After studies reported as high as a threefold increase in the risk of blood clots for Yaz and similar products, the FDA has ordered Yaz, Yasmin, Beyaz, Safyral, and some generics to change their label warnings.
The new labels are required to report the findings of the studies reporting a threefold increase in the risk of blood clots when compared to products containing some other progestin. The increased warnings come from the recommendation of an outside panel of medical experts.
Along with the increased label changes, the FDA also reminded women to speak with their doctor about their individual risks for developing blood clots. Deep vein thrombosis and pulmonary embolisms are two types of blood clots associated with Yaz and related products.